Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
Cochlear share price drops following patent infringement case update
Share Gainers
Why Aurizon, Cochlear, Magellan, & Westpac shares are pushing higher
Share Market News
Top brokers name 3 ASX shares to sell next week
Growth Shares
3 outstanding ASX shares to buy in August
Share Market News
Top brokers name 3 ASX shares to sell today
⏸️ ASX Shares
3 top ASX shares that could be quality buy and hold options
Share Fallers
Why Cochlear, NAB, Tabcorp, & Telstra shares are tumbling lower
Share Market News
Leading brokers name 3 ASX shares to sell today
Share Gainers
Why Alliance Aviation, Cochlear, Kogan, & Netwealth shares are storming higher
Share Market News
ASX 200 up 0.1%: Big four banks tumble, Flight Centre sinks, SEEK cancels final dividend
Share Market News
3 underloved ASX healthcare shares with strong comeback potential
⏸️ ASX Shares
Why I would buy these ASX 50 blue chip shares for the long term
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
